vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -6.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -7.4%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
PCRX vs SRI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $205.2M |
| Net Profit | $2.9M | — |
| Gross Margin | — | 16.2% |
| Operating Margin | 3.9% | -14.4% |
| Net Margin | 1.6% | — |
| Revenue YoY | 5.0% | -6.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $205.2M | ||
| Q3 25 | $179.5M | $210.3M | ||
| Q2 25 | $181.1M | $228.0M | ||
| Q1 25 | $168.9M | $217.9M | ||
| Q4 24 | $187.3M | $218.2M | ||
| Q3 24 | $168.6M | $213.8M | ||
| Q2 24 | $178.0M | $237.1M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-9.4M | ||
| Q2 25 | $-4.8M | $-9.4M | ||
| Q1 25 | $4.8M | $-7.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $-7.1M | ||
| Q2 24 | $18.9M | $2.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 16.2% | ||
| Q3 25 | 80.9% | 20.3% | ||
| Q2 25 | 77.4% | 21.5% | ||
| Q1 25 | 79.7% | 21.2% | ||
| Q4 24 | 78.7% | 19.5% | ||
| Q3 24 | 76.9% | 20.8% | ||
| Q2 24 | 75.1% | 22.7% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -14.4% | ||
| Q3 25 | 3.5% | -1.6% | ||
| Q2 25 | 4.7% | -1.1% | ||
| Q1 25 | 1.2% | -1.5% | ||
| Q4 24 | 13.2% | -2.0% | ||
| Q3 24 | -82.8% | 0.1% | ||
| Q2 24 | 15.9% | 1.4% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -4.5% | ||
| Q2 25 | -2.7% | -4.1% | ||
| Q1 25 | 2.8% | -3.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | -3.3% | ||
| Q2 24 | 10.6% | 1.2% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-2.76 | ||
| Q3 25 | $0.12 | $-0.34 | ||
| Q2 25 | $-0.11 | $-0.34 | ||
| Q1 25 | $0.10 | $-0.26 | ||
| Q4 24 | $0.38 | $-0.22 | ||
| Q3 24 | $-3.11 | $-0.26 | ||
| Q2 24 | $0.39 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $66.3M |
| Total DebtLower is stronger | — | $180.9M |
| Stockholders' EquityBook value | $653.9M | $179.8M |
| Total Assets | $1.2B | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $66.3M | ||
| Q3 25 | $246.3M | $54.0M | ||
| Q2 25 | $445.9M | $49.8M | ||
| Q1 25 | $493.6M | $79.1M | ||
| Q4 24 | $484.6M | $71.8M | ||
| Q3 24 | $453.8M | $54.1M | ||
| Q2 24 | $404.2M | $42.1M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $180.9M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $179.8M | ||
| Q3 25 | $727.2M | $251.2M | ||
| Q2 25 | $757.8M | $260.5M | ||
| Q1 25 | $798.5M | $253.1M | ||
| Q4 24 | $778.3M | $245.3M | ||
| Q3 24 | $749.6M | $271.4M | ||
| Q2 24 | $879.3M | $270.5M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $551.2M | ||
| Q3 25 | $1.3B | $632.1M | ||
| Q2 25 | $1.5B | $639.4M | ||
| Q1 25 | $1.6B | $657.4M | ||
| Q4 24 | $1.6B | $621.6M | ||
| Q3 24 | $1.5B | $662.5M | ||
| Q2 24 | $1.6B | $666.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 1.01× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.8M |
| Free Cash FlowOCF − Capex | — | $2.6M |
| FCF MarginFCF / Revenue | — | 1.3% |
| Capex IntensityCapex / Revenue | — | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $8.8M | ||
| Q3 25 | $60.8M | $3.6M | ||
| Q2 25 | $12.0M | $10.7M | ||
| Q1 25 | $35.5M | $10.9M | ||
| Q4 24 | $33.1M | $19.2M | ||
| Q3 24 | $53.9M | $10.8M | ||
| Q2 24 | $53.2M | $8.7M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $2.6M | ||
| Q3 25 | $57.0M | $-2.7M | ||
| Q2 25 | $9.3M | $7.4M | ||
| Q1 25 | $26.9M | $4.8M | ||
| Q4 24 | $31.0M | $14.0M | ||
| Q3 24 | $49.8M | $4.6M | ||
| Q2 24 | $51.6M | $1.5M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 1.3% | ||
| Q3 25 | 31.7% | -1.3% | ||
| Q2 25 | 5.1% | 3.3% | ||
| Q1 25 | 15.9% | 2.2% | ||
| Q4 24 | 16.6% | 6.4% | ||
| Q3 24 | 29.6% | 2.2% | ||
| Q2 24 | 29.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 2.2% | 3.0% | ||
| Q2 25 | 1.5% | 1.4% | ||
| Q1 25 | 5.1% | 2.8% | ||
| Q4 24 | 1.1% | 2.4% | ||
| Q3 24 | 2.4% | 2.9% | ||
| Q2 24 | 0.9% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | 3.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
